# Comprehensive Q&A: QALY Flow Framework for Unbounded Lifespans

This document contains questions organized by topic and audience level. Each question indicates the assumed audience, confidence level, and consistency level.

## Key

### Audience
- **[GP]** = General Public (no technical background)
- **[HE]** = Health Economics practitioner
- **[PM]** = Policy Maker / Administrator
- **[PH]** = Philosopher / Ethicist
- **[MA]** = Mathematician / Statistician
- **[MD]** = Medical / Clinical professional
- **[LE]** = Legal / Regulatory expert

### Confidence (how well we can answer from paper + existing theory)
- **⬤⬤⬤** = High — Direct answer in paper or established theory
- **⬤⬤◯** = Medium — Partial answer or requires inference
- **⬤◯◯** = Low — Speculative or outside scope of work

### Consistency (how stable the answer is across phrasings/contexts)
- **███** = High — Answer is determinate and stable
- **██░** = Medium — Core stable but details may vary
- **█░░** = Low — Very open-ended, answer could vary significantly

---

## Part 1: Basic Concepts and Motivation

### 1.1 What is this paper about?

1. What is a QALY and why does it matter for health policy? **[GP]** ⬤⬤⬤ ███
2. Why can't we just use regular QALYs if people live longer? **[GP]** ⬤⬤⬤ ███
3. What does "unbounded lifespan" actually mean—will people live forever? **[GP]** ⬤⬤⬤ ██░
4. Is this paper saying death will become optional? **[GP]** ⬤⬤◯ ██░
5. What's wrong with how we currently evaluate health treatments? **[GP]** ⬤⬤⬤ ███
6. Why does the paper talk about "maintenance" and "repair"—are we treating people like machines? **[GP]** ⬤⬤⬤ ███
7. What is the difference between lifespan and healthspan? **[GP]** ⬤⬤⬤ ███
8. If I could live indefinitely, would I want to? Is this paper assuming I would? **[GP]** ⬤⬤◯ █░░
9. What does "catastrophic failure" mean in this context? **[GP]** ⬤⬤⬤ ███
10. Why is this a problem that needs solving now? **[GP]** ⬤⬤◯ ██░

### 1.2 Setting and assumptions

11. What scientific advances would need to happen for this framework to become relevant? **[MD]** ⬤◯◯ █░░
12. How does this framework apply to current health policy, or is it purely futuristic? **[PM]** ⬤⬤◯ ██░
13. What is the timeline for when unbounded lifespans might become a reality? **[MD]** ⬤◯◯ █░░
14. Does this framework assume all diseases will be curable? **[MD]** ⬤⬤⬤ ███
15. How does the paper define "repairable" vs. "irreversible" conditions? **[MD]** ⬤⬤⬤ ███
16. What counts as a "catastrophic failure" vs. a "repairable degradation"? **[MD]** ⬤⬤⬤ ██░
17. Are there any current conditions that would be classified as "irreversible harm states"? **[MD]** ⬤⬤◯ ██░
18. Does the model account for aging as a disease vs. aging as a natural process? **[MD]** ⬤⬤◯ ██░
19. How does this relate to cryonics or other life extension technologies? **[GP]** ⬤◯◯ █░░
20. Does the paper assume people will want to live indefinitely? **[PH]** ⬤⬤⬤ ███

---

## Part 2: The Six Axioms

### 2.1 Axiom 1: Well-posedness

21. Why is it important that policy evaluation be "finite"? **[PM]** ⬤⬤⬤ ███
22. What does "stable marginal comparisons" mean in practice? **[HE]** ⬤⬤⬤ ███
23. Could you give an example of a policy evaluation that would fail the well-posedness axiom? **[HE]** ⬤⬤⬤ ███
24. How does this axiom differ from standard assumptions in cost-effectiveness analysis? **[HE]** ⬤⬤⬤ ███
25. Is well-posedness a mathematical requirement or a practical one? **[MA]** ⬤⬤⬤ ███

### 2.2 Axiom 2: Horizon invariance

26. Why should a health policy not depend on a "terminal time"? **[PM]** ⬤⬤⬤ ███
27. Doesn't all budgeting have to assume some time horizon? **[PM]** ⬤⬤◯ ██░
28. How do current health policies violate horizon invariance? **[HE]** ⬤⬤⬤ ███
29. If we don't have a fixed endpoint, how do we ever make decisions? **[PM]** ⬤⬤⬤ ███
30. Is horizon invariance compatible with democratic political cycles? **[PM]** ⬤⬤◯ ██░

### 2.3 Axiom 3: Experienced welfare as a flow

31. What does it mean that health value "accrues" rather than exists at a point in time? **[GP]** ⬤⬤⬤ ███
32. Why focus on experienced quality rather than objective health status? **[MD]** ⬤⬤⬤ ██░
33. How do we measure "instantaneous quality of life"? **[HE]** ⬤⬤⬤ ███
34. Doesn't this ignore the fact that some experiences have lasting effects? **[PH]** ⬤⬤◯ ██░
35. What about anticipation and memory—don't they affect welfare too? **[PH]** ⬤⬤◯ ██░
36. Is this axiom committed to hedonism about well-being? **[PH]** ⬤⬤◯ ██░
37. How does this relate to the EQ-5D and other quality measurement tools? **[HE]** ⬤⬤⬤ ███

### 2.4 Axiom 4: Death as truncation

38. Why shouldn't death have its own "disvalue" separate from ending future welfare? **[PH]** ⬤⬤⬤ ██░
39. Doesn't this ignore the badness of death itself (not just loss of future goods)? **[PH]** ⬤⬤◯ ██░
40. How does this axiom relate to the "deprivation account" of death's badness? **[PH]** ⬤⬤◯ ██░
41. Is this saying death is only bad because you miss out on future experiences? **[PH]** ⬤⬤⬤ ███
42. What if someone has a very low quality of life—does their death still "truncate" welfare? **[PH]** ⬤⬤⬤ ███
43. Does this framework respect autonomy around end-of-life decisions? **[MD]** ⬤⬤◯ ██░
44. How would this apply to physician-assisted dying? **[MD]** ⬤◯◯ █░░

### 2.5 Axiom 5: Explicit normativity

45. Why is it important to make ethical assumptions "explicit"? **[PH]** ⬤⬤⬤ ███
46. What does it mean that time preference is "hidden inside technical devices"? **[HE]** ⬤⬤⬤ ███
47. Isn't the choice of discount rate already debated explicitly? **[HE]** ⬤⬤⬤ ███
48. How do current NICE guidelines violate this axiom? **[HE]** ⬤⬤◯ ██░
49. What other normative commitments are typically hidden in health economics? **[PH]** ⬤⬤◯ ██░
50. Does making assumptions explicit actually change policy outcomes? **[PM]** ⬤◯◯ █░░

### 2.6 Axiom 6: Policy-relevance (person-time)

51. What does "welfare per unit of population time" mean concretely? **[PM]** ⬤⬤⬤ ███
52. How is this different from maximizing total QALYs? **[HE]** ⬤⬤⬤ ███
53. Why should governments think in terms of person-time rather than individuals? **[PM]** ⬤⬤⬤ ███
54. Doesn't this ignore the separateness of persons? **[PH]** ⬤⬤⬤ ██░
55. Is this axiom utilitarian? **[PH]** ⬤⬤⬤ ██░
56. How does this axiom relate to public health surveillance data? **[MD]** ⬤⬤◯ ██░

---

## Part 3: Interpersonal Aggregation and Fungibility

57. What does it mean to treat one person's quality-time as "substitutable" for another's? **[PH]** ⬤⬤⬤ ███
58. Is it ethical to trade off one person's health for another's? **[PH]** ⬤⬤◯ █░░
59. How does the paper justify interpersonal welfare comparisons? **[PH]** ⬤⬤⬤ ███
60. Does the paper claim QALYs are really comparable across people? **[PH]** ⬤⬤⬤ ██░
61. What is "trajectory convergence over long horizons" and why does it help? **[MA]** ⬤⬤⬤ ███
62. Doesn't everyone's experience remain unique even if lifespans are long? **[PH]** ⬤⬤◯ ██░
63. How does this relate to the capabilities approach to welfare? **[PH]** ⬤◯◯ █░░
64. Is this framework compatible with prioritarianism? **[PH]** ⬤⬤⬤ ███
65. Can the framework accommodate special obligations (to family, etc.)? **[PH]** ⬤⬤◯ ██░

---

## Part 4: The Mathematical Model

### 4.1 State space and dynamics

66. What is a "controlled continuous-time Markov chain"? **[GP]** ⬤⬤⬤ ███
67. Why use continuous time rather than discrete time steps? **[MA]** ⬤⬤⬤ ███
68. What are the states in a realistic health state space? **[MD]** ⬤⬤◯ ██░
69. How many states would a realistic model need? **[HE]** ⬤◯◯ █░░
70. Can the state space be infinite? **[MA]** ⬤⬤⬤ ███
71. What is a "rate kernel" and how is it estimated? **[MA]** ⬤⬤⬤ ██░
72. How do transition rates vary with age in this model? **[MA]** ⬤⬤◯ ██░
73. Does the model allow for time-varying transition rates? **[MA]** ⬤⬤⬤ ███
74. What is "non-explosiveness" and why does it matter? **[MA]** ⬤⬤⬤ ███
75. What are Foster-Lyapunov criteria and when do they apply? **[MA]** ⬤⬤⬤ ███
76. Can the model handle correlated health states (comorbidities)? **[MD]** ⬤⬤⬤ ███
77. How does one estimate transition probabilities from epidemiological data? **[HE]** ⬤⬤◯ ██░

### 4.2 Actions and policies

78. What counts as an "action" in this framework? **[HE]** ⬤⬤⬤ ███
79. Can actions include social determinants of health (housing, income)? **[PM]** ⬤⬤⬤ ██░
80. What is a "stationary Markov policy"? **[MA]** ⬤⬤⬤ ███
81. Why restrict to stationary policies—aren't some policies naturally time-varying? **[HE]** ⬤⬤⬤ ███
82. How does the model handle multi-agent decisions (patient + doctor + insurer)? **[HE]** ⬤◯◯ █░░
83. Can the framework model preventive vs. curative interventions differently? **[MD]** ⬤⬤⬤ ███
84. What if the action space is continuous (e.g., drug dosage)? **[MA]** ⬤⬤⬤ ██░

### 4.3 The regeneration assumption

85. Why does the model assume "immediate replacement" after death? **[GP]** ⬤⬤⬤ ███
86. Is this saying one person's death doesn't matter because someone else comes along? **[PH]** ⬤⬤⬤ ███
87. How realistic is the i.i.d. assumption for new entrants? **[MA]** ⬤⬤⬤ ███
88. What if the initial health distribution changes over time (demographic shifts)? **[HE]** ⬤⬤◯ ██░
89. How does this relate to overlapping generations models in economics? **[HE]** ⬤⬤◯ ██░
90. What if birth rates decline—does the framework still apply? **[PM]** ⬤⬤◯ ██░
91. How does immigration affect the regeneration assumption? **[PM]** ⬤⬤◯ ██░
92. Is this assumption necessary or just convenient? **[MA]** ⬤⬤⬤ ███
93. What happens if we relax the independence assumption? **[MA]** ⬤⬤◯ ██░

---

## Part 5: QALY Flow and Cost Flow

### 5.1 Definition and interpretation

94. What exactly is "QALY flow"—is it a rate or a ratio? **[HE]** ⬤⬤⬤ ███
95. How do you interpret J(π) = 0.7 in practical terms? **[PM]** ⬤⬤⬤ ███
96. Why is J(π) always between 0 and 1? **[MA]** ⬤⬤⬤ ███
97. What does K(π) (cost flow) represent in budget terms? **[PM]** ⬤⬤⬤ ███
98. How do you convert QALY flow to a monetary value? **[HE]** ⬤⬤◯ ██░
99. Is there a "threshold" for acceptable QALY flow like the £30,000/QALY threshold? **[PM]** ⬤◯◯ █░░
100. How does QALY flow compare to quality-adjusted life expectancy? **[HE]** ⬤⬤⬤ ███

### 5.2 The renewal-reward theorem

101. What is renewal-reward theory and where does it come from? **[MA]** ⬤⬤⬤ ███
102. Can you explain the theorem in plain language? **[GP]** ⬤⬤⬤ ███
103. What conditions are needed for the theorem to hold? **[MA]** ⬤⬤⬤ ███
104. What happens if the expected cycle length is infinite? **[MA]** ⬤⬤⬤ ███
105. Does the theorem require ergodicity? **[MA]** ⬤⬤⬤ ███
106. How quickly does Q(T)/T converge to J(π)? **[MA]** ⬤⬤◯ ██░
107. What is the rate of convergence and does it matter for policy? **[HE]** ⬤⬤◯ ██░
108. Can you prove the theorem? **[MA]** ⬤⬤⬤ ███

### 5.3 Truncated flow

109. Why do we need the truncated flow definition? **[HE]** ⬤⬤⬤ ███
110. What does J⁺(π) ≠ J⁻(π) mean intuitively? **[MA]** ⬤⬤⬤ ███
111. Under what conditions do the limsup and liminf agree? **[MA]** ⬤⬤⬤ ███
112. Is there a policy where J⁺ ≠ J⁻? Can you give an example? **[MA]** ⬤⬤◯ ██░
113. How does truncation relate to discounting? **[HE]** ⬤⬤⬤ ███
114. Is truncated flow the same as using a very low discount rate? **[HE]** ⬤⬤⬤ ███

---

## Part 6: Risk Neutrality and Extensions

### 6.1 Risk neutrality

115. What does "risk neutral" mean in this context? **[GP]** ⬤⬤⬤ ███
116. Why is the base framework risk neutral? **[HE]** ⬤⬤⬤ ███
117. Shouldn't health policy be risk averse? **[PH]** ⬤⬤◯ ██░
118. How do you add risk aversion to the framework? **[MA]** ⬤⬤⬤ ███
119. What is the mean-variance objective and when is it appropriate? **[MA]** ⬤⬤⬤ ███
120. What is CVaR and why use it instead of variance? **[MA]** ⬤⬤⬤ ███
121. How do you choose the risk aversion parameter λ or α? **[PM]** ⬤◯◯ █░░
122. Is risk neutrality ever the right choice for health policy? **[PM]** ⬤⬤◯ ██░

### 6.2 Irreversibility

123. Why treat irreversibility separately from quality? **[HE]** ⬤⬤⬤ ███
124. What is "option value loss" and why does it matter? **[HE]** ⬤⬤⬤ ███
125. Should irreversibility be a penalty or a constraint? **[PH]** ⬤⬤◯ █░░
126. How do you set the irreversibility penalty κ(x)? **[HE]** ⬤◯◯ █░░
127. What if we disagree about which states are irreversible? **[MD]** ⬤⬤◯ ██░
128. How does irreversibility relate to disability rights arguments? **[PH]** ⬤◯◯ █░░
129. Doesn't treating irreversibility as a penalty devalue disabled lives? **[PH]** ⬤⬤◯ ██░

### 6.3 Volatility

130. Why does volatility matter if the average is the same? **[GP]** ⬤⬤⬤ ███
131. What causes cycle-to-cycle volatility in quality? **[MD]** ⬤⬤◯ ██░
132. Is Assumption 5 (minimum cycle length) realistic? **[MD]** ⬤⬤◯ ██░
133. How do you estimate variance of q̄^π from data? **[HE]** ⬤⬤◯ ██░
134. What if people prefer some volatility (e.g., for hope)? **[PH]** ⬤◯◯ █░░

---

## Part 7: Optimization and Computation

### 7.1 Existence of optimal policies

135. Does an optimal policy always exist? **[MA]** ⬤⬤⬤ ███
136. What if there are infinitely many policies? **[MA]** ⬤⬤⬤ ███
137. Why is the finite-state case easier? **[MA]** ⬤⬤⬤ ███
138. What computational methods can find optimal policies? **[MA]** ⬤⬤⬤ ██░
139. How does linear-fractional programming work for this problem? **[MA]** ⬤⬤⬤ ███
140. What is average-reward dynamic programming? **[MA]** ⬤⬤⬤ ███
141. Can reinforcement learning methods be applied? **[MA]** ⬤⬤◯ ██░
142. How does the optimization scale with state space size? **[MA]** ⬤⬤◯ ██░
143. Are there approximate methods for large state spaces? **[MA]** ⬤⬤◯ ██░

### 7.2 Policy comparison

144. How do you compare two policies when one is better on J and worse on K? **[PM]** ⬤⬤⬤ ███
145. What is the willingness-to-pay parameter λ and how is it set? **[PM]** ⬤⬤⬤ ██░
146. Is W_λ(f) = J(f) - λK(f) the only way to combine quality and cost? **[HE]** ⬤⬤⬤ ██░
147. What if costs are uncertain—does the framework handle stochastic costs? **[MA]** ⬤⬤⬤ ███

---

## Part 8: Sensitivity Analysis

### 8.1 Lipschitz stability

148. What does "Lipschitz stability" mean in plain language? **[GP]** ⬤⬤⬤ ███
149. Why is stability important for policy decisions? **[PM]** ⬤⬤⬤ ███
150. What could cause instability in the QALY flow metric? **[HE]** ⬤⬤⬤ ███
151. How do you verify Assumptions 4 and 5 (uniform bounds, Lipschitz) in practice? **[HE]** ⬤⬤◯ ██░
152. Can you prove Theorem 3 (Lipschitz stability)? **[MA]** ⬤⬤⬤ ███
153. What is the Lipschitz constant (L_R + L_τ)/m and is it tight? **[MA]** ⬤⬤⬤ ██░
154. What happens when the lower bound m approaches zero? **[MA]** ⬤⬤⬤ ███
155. How does this compare to sensitivity analysis in traditional CEA? **[HE]** ⬤⬤◯ ██░

### 8.2 Parameter uncertainty

156. How do you propagate uncertainty through the QALY flow calculation? **[HE]** ⬤⬤◯ ██░
157. Should you do probabilistic sensitivity analysis with this framework? **[HE]** ⬤⬤⬤ ██░
158. What parameters are typically most uncertain? **[HE]** ⬤⬤◯ ██░
159. How do you handle model uncertainty (not just parameter uncertainty)? **[HE]** ⬤◯◯ █░░
160. Does the framework support value of information analysis? **[HE]** ⬤⬤◯ ██░

---

## Part 9: Cost-Effectiveness

### 9.1 Flow ICER

161. How is the flow ICER different from the standard ICER? **[HE]** ⬤⬤⬤ ███
162. What are the units of the flow ICER? **[HE]** ⬤⬤⬤ ███
163. Can flow ICER be negative? What does that mean? **[HE]** ⬤⬤⬤ ███
164. How do you interpret a flow ICER of £20,000 per unit J? **[PM]** ⬤⬤⬤ ██░
165. Should regulators set a threshold for flow ICER? **[PM]** ⬤◯◯ █░░
166. How would existing NICE thresholds translate to this framework? **[HE]** ⬤◯◯ █░░
167. Does the flow ICER avoid problems with extended dominance? **[HE]** ⬤⬤◯ ██░

### 9.2 Budget impact

168. How do you assess budget impact using cost flow K(π)? **[PM]** ⬤⬤⬤ ███
169. Can you use this framework for multi-year budget planning? **[PM]** ⬤⬤◯ ██░
170. How does K(π) relate to annual health expenditure? **[PM]** ⬤⬤⬤ ███
171. Does the framework account for capital costs vs. operating costs? **[HE]** ⬤⬤◯ ██░

---

## Part 10: Distributional Concerns

### 10.1 Equity weighting

172. How do you assign equity weights w_i to different groups? **[PM]** ⬤⬤◯ ██░
173. Should weights be based on health need, income, or something else? **[PH]** ⬤◯◯ █░░
174. How does this relate to the "fair innings" argument? **[PH]** ⬤⬤◯ ██░
175. Can the framework handle intersectional inequalities? **[PH]** ⬤⬤◯ ██░
176. What if groups have different quality functions q_i(x)? **[HE]** ⬤⬤⬤ ███

### 10.2 Social welfare functions

177. What is inequality-averse social welfare and why use concave u? **[HE]** ⬤⬤⬤ ███
178. How do you choose the social welfare function? **[PH]** ⬤◯◯ █░░
179. Can you use Rawlsian maximin with this framework? **[PH]** ⬤⬤⬤ ███
180. What is the "minimum acceptable flow" constraint and who sets it? **[PM]** ⬤⬤⬤ ██░
181. Is there a human right to a certain QALY flow? **[LE]** ⬤◯◯ █░░

### 10.3 Intergenerational equity

182. Does the framework treat current and future generations equally? **[PH]** ⬤⬤⬤ ███
183. How do you handle population growth in the distributional analysis? **[HE]** ⬤⬤◯ ██░
184. What if future generations will have different quality functions? **[PH]** ⬤⬤◯ ██░
185. Does this framework conflict with sustainability considerations? **[PM]** ⬤◯◯ █░░

---

## Part 11: Philosophical Foundations

### 11.1 Welfarism and experience

186. Is the framework committed to welfarism? **[PH]** ⬤⬤⬤ ██░
187. Can the framework accommodate objective list theories of well-being? **[PH]** ⬤⬤◯ ██░
188. What about preference satisfaction views? **[PH]** ⬤⬤◯ ██░
189. Does the focus on experience ignore the value of achievements? **[PH]** ⬤⬤◯ ██░
190. How does this relate to Parfit's work on personal identity? **[PH]** ⬤◯◯ █░░
191. If someone is uploaded to a digital substrate, does the framework still apply? **[PH]** ⬤◯◯ █░░

### 11.2 Time and personal identity

192. Does the framework assume psychological continuity theory of identity? **[PH]** ⬤⬤◯ ██░
193. What if "I" in 200 years is not really "me"? **[PH]** ⬤⬤◯ █░░
194. Does extreme longevity create problems for personal identity? **[PH]** ⬤◯◯ █░░
195. Should QALYs be discounted for psychological distance? **[PH]** ⬤⬤◯ ██░
196. How does the framework handle amnesia or major personality changes? **[PH]** ⬤◯◯ █░░

### 11.3 Value of life and death

197. Does the framework assume life is always preferable to death? **[PH]** ⬤⬤⬤ ███
198. What about cases where someone rationally prefers death? **[PH]** ⬤⬤◯ ██░
199. Does the framework respect the "right to die"? **[LE]** ⬤⬤◯ ██░
200. How does the framework handle states worse than death? **[HE]** ⬤⬤⬤ ███
201. Can q(x) be negative? **[HE]** ⬤⬤⬤ ███
202. What is the implicit value of a statistical life in this framework? **[HE]** ⬤⬤◯ ██░

### 11.4 Population ethics

203. Does the framework have a position on the "repugnant conclusion"? **[PH]** ⬤⬤◯ ██░
204. Is adding new lives (via the regeneration assumption) good or neutral? **[PH]** ⬤⬤◯ ██░
205. How does this relate to total vs. average utilitarianism? **[PH]** ⬤⬤⬤ ███
206. Does the framework favor extending existing lives or creating new ones? **[PH]** ⬤⬤⬤ ██░
207. What is the framework's position on the non-identity problem? **[PH]** ⬤◯◯ █░░

---

## Part 12: Comparison with Existing Approaches

### 12.1 Discounting

208. Why not just use standard discounted QALYs with a low discount rate? **[HE]** ⬤⬤⬤ ███
209. What discount rate would make discounted QALYs equivalent to QALY flow? **[MA]** ⬤⬤⬤ ███
210. Does the framework make discounting obsolete? **[HE]** ⬤⬤⬤ ██░
211. What if society genuinely has pure time preference? **[PH]** ⬤⬤◯ ██░
212. How does hyperbolic discounting fit into this framework? **[HE]** ⬤⬤◯ ██░
213. Can you combine QALY flow with some discounting? **[HE]** ⬤⬤◯ ██░

### 12.2 Health-adjusted life expectancy

214. How does QALY flow relate to HALE (Health-Adjusted Life Expectancy)? **[HE]** ⬤⬤⬤ ███
215. Can QALY flow be computed from HALE data? **[HE]** ⬤⬤◯ ██░
216. What does QALY flow add beyond existing population health measures? **[PM]** ⬤⬤⬤ ███

### 12.3 Disability-adjusted life years

217. Could you define a DALY flow analogous to QALY flow? **[HE]** ⬤⬤⬤ ███
218. How would the axioms change for burden-of-disease measurement? **[HE]** ⬤⬤◯ ██░
219. Does the Global Burden of Disease study use anything like this? **[HE]** ⬤⬤◯ ██░

### 12.4 Other frameworks

220. How does this compare to the capability approach? **[PH]** ⬤◯◯ █░░
221. What about wellbeing-adjusted life years (WELLBYs)? **[HE]** ⬤⬤◯ ██░
222. How does this relate to the "health years equivalent" concept? **[HE]** ⬤⬤◯ ██░
223. Is this compatible with multi-criteria decision analysis? **[HE]** ⬤⬤◯ ██░

---

## Part 13: Practical Implementation

### 13.1 Data requirements

224. What data would you need to implement this framework? **[HE]** ⬤⬤◯ ██░
225. Can this be estimated from existing health surveys? **[HE]** ⬤⬤◯ ██░
226. How do you estimate transition rates for very rare events? **[MA]** ⬤⬤◯ ██░
227. What longitudinal data sources would be most useful? **[HE]** ⬤⬤◯ ██░
228. Can electronic health records be used for calibration? **[MD]** ⬤⬤◯ ██░

### 13.2 Calibration

229. How do you calibrate the quality function q(x)? **[HE]** ⬤⬤⬤ ██░
230. What if different EQ-5D tariffs give different q values? **[HE]** ⬤⬤⬤ ██░
231. How do you handle states not covered by existing instruments? **[HE]** ⬤⬤◯ ██░
232. Should q be calibrated to community or patient preferences? **[PH]** ⬤⬤◯ █░░
233. How do you calibrate costs c(x,a)? **[HE]** ⬤⬤◯ ██░

### 13.3 Model validation

234. How would you validate a QALY flow model? **[HE]** ⬤◯◯ █░░
235. What would count as evidence that the framework works? **[HE]** ⬤◯◯ █░░
236. Can you back-test against historical health data? **[HE]** ⬤⬤◯ ██░
237. How do you check that the model predicts out-of-sample? **[MA]** ⬤⬤◯ ██░

### 13.4 Decision making

238. How would a regulator use this framework in practice? **[PM]** ⬤⬤◯ ██░
239. What would a QALY flow-based health technology assessment look like? **[HE]** ⬤⬤◯ ██░
240. How do you communicate QALY flow results to policymakers? **[PM]** ⬤⬤◯ ██░
241. Should patients understand QALY flow? **[MD]** ⬤⬤◯ ██░
242. How do you handle disagreement about model parameters? **[PM]** ⬤⬤◯ ██░

---

## Part 14: Legal and Regulatory Issues

243. Is QALY flow compatible with existing health law? **[LE]** ⬤◯◯ █░░
244. Could this framework be challenged on discrimination grounds? **[LE]** ⬤◯◯ █░░
245. How does this interact with the right to health? **[LE]** ⬤◯◯ █░░
246. What are the implications for insurance regulation? **[LE]** ⬤◯◯ █░░
247. Could this affect clinical negligence standards? **[LE]** ⬤◯◯ █░░
248. How would FDA/EMA evaluate drugs using this framework? **[LE]** ⬤◯◯ █░░
249. Does this framework have implications for informed consent? **[LE]** ⬤◯◯ █░░
250. How does it interact with age discrimination law? **[LE]** ⬤◯◯ █░░

---

## Part 15: Specific Applications

### 15.1 Disease areas

251. How would you apply this to cancer treatment evaluation? **[MD]** ⬤⬤◯ ██░
252. What about chronic disease management (diabetes, heart disease)? **[MD]** ⬤⬤◯ ██░
253. How does this apply to mental health conditions? **[MD]** ⬤⬤◯ ██░
254. What about rare diseases with uncertain prognosis? **[MD]** ⬤⬤◯ ██░
255. How would you evaluate aging interventions (senolytics, etc.)? **[MD]** ⬤⬤◯ ██░
256. What about organ replacement or regeneration? **[MD]** ⬤⬤◯ ██░
257. How would brain-computer interfaces be evaluated? **[MD]** ⬤◯◯ █░░

### 15.2 Intervention types

258. How would you evaluate preventive vs. curative interventions? **[HE]** ⬤⬤⬤ ███
259. What about public health interventions (vaccines, sanitation)? **[PM]** ⬤⬤⬤ ██░
260. How would you evaluate lifestyle interventions? **[MD]** ⬤⬤◯ ██░
261. What about genetic therapies with permanent effects? **[MD]** ⬤⬤◯ ██░
262. How would you evaluate palliative care? **[MD]** ⬤⬤⬤ ██░

### 15.3 Edge cases

263. What if a treatment makes you immortal but paralyzed? **[PH]** ⬤⬤⬤ ███
264. What about treatments that extend lifespan but reduce quality? **[HE]** ⬤⬤⬤ ███
265. How do you evaluate a treatment that has a small chance of cure and a large chance of death? **[HE]** ⬤⬤⬤ ███
266. What about treatments that work for some people but not others? **[HE]** ⬤⬤⬤ ███
267. How do you handle treatments with very long lag times before benefit? **[HE]** ⬤⬤⬤ ███

---

## Part 16: Critiques and Objections

### 16.1 Theoretical objections

268. Isn't this just discounting with r=0? **[HE]** ⬤⬤⬤ ███
269. Why should we accept the axioms? **[PH]** ⬤⬤◯ █░░
270. Doesn't the regeneration assumption make this population-level not individual-level? **[HE]** ⬤⬤⬤ ███
271. What if the axioms are mutually inconsistent? **[MA]** ⬤⬤⬤ ███
272. Is there a representation theorem showing these axioms uniquely determine J(π)? **[MA]** ⬤⬤◯ ██░
273. What alternative objectives could satisfy the same axioms? **[MA]** ⬤⬤◯ ██░

### 16.2 Practical objections

274. Is this too complicated for real-world use? **[PM]** ⬤⬤◯ ██░
275. Doesn't this require too much data? **[HE]** ⬤⬤◯ ██░
276. How can you validate predictions about unbounded lifespans with finite data? **[MA]** ⬤⬤◯ ██░
277. Isn't this premature given current life expectancy? **[PM]** ⬤⬤⬤ ██░
278. What if longevity technology never arrives—is this framework still useful? **[PM]** ⬤⬤⬤ ███

### 16.3 Ethical objections

279. Doesn't this devalue the lives of people who die young? **[PH]** ⬤⬤⬤ ███
280. Is it fair to evaluate policies based on an assumption most people alive today won't benefit from? **[PH]** ⬤⬤◯ ██░
281. Doesn't the person-time focus ignore individual rights? **[PH]** ⬤⬤◯ ██░
282. Is this a form of "welfarist imperialism"? **[PH]** ⬤◯◯ █░░
283. What about people who don't want extended lifespans? **[PH]** ⬤⬤⬤ ███
284. Does this framework respect diversity in conceptions of the good life? **[PH]** ⬤⬤◯ ██░

---

## Part 17: Extensions and Future Work

### 17.1 Model extensions

285. How would you extend this to multiple populations? **[HE]** ⬤⬤◯ ██░
286. Can the framework handle correlated individual outcomes (epidemics)? **[HE]** ⬤⬤◯ ██░
287. How would you model healthcare capacity constraints? **[HE]** ⬤◯◯ █░░
288. Can this be extended to game-theoretic settings? **[MA]** ⬤◯◯ █░░
289. How would you incorporate learning about treatment effects? **[MA]** ⬤◯◯ █░░
290. Can the framework handle ambiguity (Knightian uncertainty)? **[MA]** ⬤◯◯ █░░

### 17.2 Methodological questions

291. Should there be a "second panel" for unbounded-lifespan methodology? **[HE]** ⬤⬤⬤ ██░
292. What should guidelines for QALY flow analysis look like? **[HE]** ⬤⬤◯ █░░
293. How should uncertainty be reported in QALY flow analyses? **[HE]** ⬤⬤◯ ██░
294. What training would analysts need? **[HE]** ⬤◯◯ █░░

### 17.3 Research agenda

295. What empirical studies would most advance this agenda? **[HE]** ⬤⬤◯ █░░
296. What theoretical results are most needed? **[MA]** ⬤⬤◯ █░░
297. What interdisciplinary work is required? **[HE]** ⬤◯◯ █░░
298. How should this research be funded? **[PM]** ⬤◯◯ █░░

---

## Part 18: Cross-Cutting Questions

### 18.1 Meta-questions

299. Who is the intended audience for this paper? **[GP]** ⬤⬤⬤ ███
300. What would it take to convince skeptics of this approach? **[PM]** ⬤⬤◯ █░░
301. What are the strongest arguments against this framework? **[PH]** ⬤⬤◯ ██░
302. What would falsify this framework? **[MA]** ⬤⬤◯ ██░
303. Is this framework normative or positive? **[PH]** ⬤⬤⬤ ███
304. What are the authors' own views that are not in the paper? **[GP]** ⬤◯◯ █░░

### 18.2 Historical and contextual

305. What is the intellectual history of this idea? **[HE]** ⬤⬤◯ ██░
306. How does this relate to the work of Bauer, Lakdawalla, and Reif? **[HE]** ⬤⬤⬤ ███
307. What role did renewal-reward theory play in other fields before health economics? **[MA]** ⬤⬤◯ ██░
308. Are there any prior attempts at similar frameworks? **[HE]** ⬤⬤◯ ██░

### 18.3 Societal implications

309. If this framework were adopted, how would it change health priorities? **[PM]** ⬤⬤◯ █░░
310. Would this increase or decrease health spending? **[PM]** ⬤◯◯ █░░
311. Would this favor young or old patients? **[PH]** ⬤⬤◯ ██░
312. How would this affect the politics of health policy? **[PM]** ⬤◯◯ █░░
313. Could this be used to justify rationing? **[LE]** ⬤⬤◯ ██░
314. What are the unintended consequences of adopting this framework? **[PM]** ⬤◯◯ █░░
315. Would this change incentives for medical research? **[MD]** ⬤⬤◯ █░░

---

## Part 19: Specific Proofs and Technical Details

### 19.1 Proposition 1 (Basic boundedness)

316. Can you provide an alternative proof of Proposition 1? **[MA]** ⬤⬤⬤ ██░
317. What happens if we allow q(x) > 1 or q(x) < 0? **[MA]** ⬤⬤⬤ ███
318. Is boundedness preserved under the extensions (risk, irreversibility)? **[MA]** ⬤⬤◯ ██░

### 19.2 Theorem 1 (Renewal-reward)

319. What is the proof of the renewal-reward theorem? **[MA]** ⬤⬤⬤ ███
320. Does the theorem extend to non-i.i.d. cycles? **[MA]** ⬤⬤◯ ██░
321. What are the weakest conditions under which the theorem holds? **[MA]** ⬤⬤◯ ██░
322. Is the convergence uniform over policies? **[MA]** ⬤⬤◯ ██░
323. Can you give a counterexample where the theorem fails? **[MA]** ⬤⬤◯ ██░

### 19.3 Theorem 2 (Optimal policy existence)

324. Is the proof of Theorem 2 complete as given? **[MA]** ⬤⬤⬤ ███
325. Can you extend to countable state spaces? **[MA]** ⬤⬤◯ ██░
326. What if some policies have undefined J(f)? **[MA]** ⬤⬤◯ ██░
327. Is the optimal policy unique? **[MA]** ⬤⬤⬤ ███

### 19.4 Theorem 3 (Lipschitz stability)

328. Is the Lipschitz bound tight? Can you achieve equality? **[MA]** ⬤⬤◯ ██░
329. What happens if Assumption 4 (lower bound m) is violated? **[MA]** ⬤⬤⬤ ███
330. Can you get Hölder continuity with weaker assumptions? **[MA]** ⬤◯◯ █░░
331. How does the proof use the ratio structure of J(π)? **[MA]** ⬤⬤⬤ ███

### 19.5 Proposition 4 (Cross-sectional interpretation)

332. What is the "inspection paradox" mentioned in the proof? **[MA]** ⬤⬤⬤ ███
333. How does this relate to Palm calculus? **[MA]** ⬤⬤◯ ██░
334. Can you make the convergence quantitative? **[MA]** ⬤⬤◯ ██░

---

## Part 20: Hypotheticals and Thought Experiments

335. If a policy gives J = 0.9 but K is very high, should we adopt it? **[PM]** ⬤⬤◯ ██░
336. Suppose two policies have the same J but different cycle length distributions—should we prefer one? **[PH]** ⬤⬤◯ ██░
337. What if a policy maximizes J but only for a privileged group? **[PH]** ⬤⬤⬤ ███
338. Imagine a treatment that grants immortality but at quality 0.3—is it worth pursuing? **[PH]** ⬤⬤◯ █░░
339. What if we could guarantee J = 1 for everyone at infinite cost—what's the right policy? **[PH]** ⬤⬤◯ █░░
340. Suppose cycle lengths become so long that no one ever completes a cycle—does the framework break? **[MA]** ⬤⬤⬤ ███
341. What if a treatment eliminates catastrophic failure entirely—what happens to the regeneration assumption? **[MA]** ⬤⬤⬤ ███
342. Imagine two societies with identical J but different distributions of cycle outcomes—which is better? **[PH]** ⬤⬤◯ ██░
343. What if people could choose their own q function—should we let them? **[PH]** ⬤⬤◯ █░░
344. Suppose an alien civilization offers immortality but you must leave Earth—how do we evaluate? **[PH]** ⬤◯◯ █░░
345. What if memory could be erased after each "cycle"—does personal identity matter? **[PH]** ⬤◯◯ █░░
346. Imagine a treatment that cures all disease but causes sterility—how do we evaluate with this framework? **[PH]** ⬤⬤◯ ██░
347. What if AI systems could experience quality-of-life—should they be in the framework? **[PH]** ⬤◯◯ █░░
348. Suppose some people value extreme longevity and others don't—can one framework serve both? **[PM]** ⬤⬤◯ ██░
349. What if the quality function changes over time as society evolves—is J(π) still meaningful? **[PH]** ⬤⬤◯ ██░
350. Imagine we discover death has positive externalities (new ideas from new people)—does this change anything? **[PH]** ⬤⬤◯ █░░

---

## Part 21: Final Questions

351. What is the single most important takeaway from this paper? **[GP]** ⬤⬤⬤ ██░
352. What would the authors want readers to do after reading this? **[GP]** ⬤⬤◯ █░░
353. If you could ask the authors one question, what would it be? **[GP]** ⬤◯◯ █░░
354. What's missing from this paper that should be there? **[HE]** ⬤⬤◯ █░░
355. What's the next paper that should be written following this one? **[HE]** ⬤⬤◯ █░░
356. In 50 years, will this paper be remembered? Why or why not? **[GP]** ⬤◯◯ █░░
357. What would change if this framework were universally adopted? **[PM]** ⬤⬤◯ █░░
358. What's the biggest obstacle to adoption? **[PM]** ⬤⬤◯ ██░
359. What would make this paper wrong? **[MA]** ⬤⬤◯ ██░
360. What would make this paper unnecessary? **[PM]** ⬤⬤◯ ██░

---

*Total: 360 questions across 21 sections, covering general public through expert audiences, now annotated with confidence and consistency ratings*
